In head-to-head studies, EndoPredict’s risk classification more accurately predicted patient observed risk than the leading competitor ‐ especially in years 5 to 10.3
EndoPredict has broad insurance coverage, including Medicare and most commercial payers. For patients who encounter financial hardship, Myriad’s financial assistance programs can address a patient’s individual needs.
Learn more here: Myriad Promise.
for pre- and post-menopausal
women, diagnosed with ER+,
HER2− early-stage breast
cancer with either node-
negative or node-positive
disease (1- 3 nodes).2